Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D05NIR
|
||||
| Former ID |
DIB003804
|
||||
| Drug Name |
ALX-0061
|
||||
| Synonyms |
Nanobody therapeutic (autoimmune/inflammatory disease), Ablynx; Anti-IL-6R nanobody therapeutic (autoimmune/inflammatory disease), Ablynx
|
||||
| Drug Type |
Antibody
|
||||
| Indication | Autoimmune diabetes [ICD10:E08-E13] | Phase 2 | [1], [2] | ||
| Company |
Ablynx NV
|
||||
| Target and Pathway | |||||
| Target(s) | Interleukin-6 receptor | Target Info | [3] | ||
| KEGG Pathway | Cytokine-cytokine receptor interaction | ||||
| HIF-1 signaling pathway | |||||
| PI3K-Akt signaling pathway | |||||
| Jak-STAT signaling pathway | |||||
| Hematopoietic cell lineage | |||||
| Non-alcoholic fatty liver disease (NAFLD) | |||||
| Reactome | MAPK3 (ERK1) activation | ||||
| MAPK1 (ERK2) activation | |||||
| WikiPathways | SIDS Susceptibility Pathways | ||||
| Senescence and Autophagy in Cancer | |||||
| IL-6 signaling pathway | |||||
| Differentiation Pathway | |||||
| Interleukin-6 signaling | |||||
| References | |||||
| REF 1 | ClinicalTrials.gov (NCT02287922) A Phase IIb Study for ALX-0061 Monotherapy in Subjects With Rheumatoid Arthritis. U.S. National Institutes of Health. | ||||
| REF 2 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8363). | ||||
| REF 3 | The preclinical pharmacology of the high affinity anti-IL-6R Nanobody? ALX-0061 supports its clinical development in rheumatoid arthritis. Arthritis Res Ther. 2015 May 20;17:135. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.